First‐year quality of life assessment of an intra‐arterial (RADPLAT) versus intravenous chemoradiation phase III trial

Abstract

During treatment, significantly fewer problems with nausea and vomiting occurred in IA than in IV patients. Both groups showed improved voicing and oral intake during follow-up, often exceeding pretreatment values at 1 year.